Conversely, among the MDGs, low expression of ATP8A1 was commonly associated with tumor grades (G2 and G3) and unfavorable clinical outcomes (treatment response-PD, SD, and post-treatment outcome-RP) (Fig. 4D). This evidence concerns the gene ATP8A1 and neoplasm.